11.08.2016

Common cough remedy to be tested as potential fibromyalgia treatment

This article on dextromethorphan for fibromyalgia originally published on NationalPainReport.com and is being reprinted here with permission from the editor.  University of Alabama at Birmingham (UAB) researcher Dr. Jarred Younger has improved the lives of thousands of fibromyalgia sufferers through his research on low-dose naltrexone (LDN). Now, he’s hoping to repeat that success with the first trial using dextromethorphan (DXM), an ingredient commonly found in cough syrup, as a potential treatment for fibromyalgia. Younger and his team will recruit 15 fibromyalgia patients this … [Read more...]

10.07.2016

Eli Lilly settles Cymbalta withdrawal lawsuits

This update on the Cymbalta lawsuit settlement was first published on NationalPainReport.com. It is being  republished here with permission from the editor.  Drugmaker Eli Lilly and Company has quietly settled hundreds of personal injury lawsuits involving patients who claim they experienced withdrawal symptoms while quitting Cymbalta. When asked for an update on the cases, Robin McCall, media relations director for Baum, Hedlund, Aristei & Goldman, P.C., one of the firms handling the cases, wrote in an email, “All we can say is that the suit has been resolved.” Lilly is also … [Read more...]

09.19.2016

Potential fibromyalgia treatment is put on hold

This story on the Tonmya fibromyalgia trial originally appeared on NationalPainReport.com and is being republished here with permission from the editor.  The fibromyalgia community received some bad news earlier this month when Tonix Pharmaceuticals Holding Corp. announced TNX-102 SL (trade name: Tonmya), a low-dose, sublingual form of cyclobenzaprine (Flexeril), did not achieve the primary goal of pain relief in its latest clinical trial. The company will no longer seek approval from the U.S. Food and Drug Administration (FDA) for TNX-102 SL as a treatment for fibromyalgia. TNX-102 SL … [Read more...]

08.30.2016

Proove Fibromyalgia Profile could improve diagnosis, treatment

This article on the Proove Fibromyalgia Profile was first published on NationalPainReport.com. It is being reprinted here with permission from the editor.  The new Proove Fibromyalgia Profile ... Proove Biosciences, a California-based firm specializing in pain medicine, has developed a new tool to help physicians better diagnose and treat fibromyalgia. “The Proove Fibromyalgia Profile is a first-of-its-kind decision-improvement tool that harnesses individualized information to aid in the identification of genetic factors that may contribute to differing clinical pathways behind a … [Read more...]

08.10.2016

Ask the doctors: Is fibromyalgia progressive?

This article, "Ask the Doctors: Is fibromyalgia progressive?," was originally published on NationalPainReport.com. It is being republished here with permission from the editor.  At one time or another, all of us with fibromyalgia have wondered (and maybe even feared), “Is fibromyalgia progressive? Are my symptoms going to worsen over time?” Based on current research, fibromyalgia doesn’t appear to be degenerative, but I know a lot of us who live with this debilitating condition – myself included – question that conclusion. For many of us, it definitely feels like it’s getting worse! … [Read more...]

08.01.2016

EULAR’s revised fibromyalgia recommendations are more of the same

This story about EULAR's revised fibromyalgia recommendations was originally published on NationalPainReport.com. It is being republished here with permission from the editor. Earlier this month, the European League Against Rheumatism (EULAR) released its revised recommendations for the management of fibromyalgia. Unfortunately, there’s nothing really new about EULAR’s latest report. The group’s main conclusion is something every fibromyalgia sufferer has heard from their physician: “Based on meta-analyses, the only ‘strong for’ therapy-based recommendation in the guidelines was … [Read more...]

07.26.2016

What the research really says about using opioids for fibromyalgia

This story on using opioids for fibromyalgia first published on NationalPainReport.com. It is being reprinted here with permission from the editor.  Using opioids for fibromyalgia My fibromyalgia and primary-care doctors have always been united when it comes to one thing: Opioids do not relieve fibromyalgia pain! Early on, I believed them and didn’t question their treatment plans. I figured they must have formed their opinions based on actual clinical trials. Turns out, I was wrong. The reality is there have been no sizable, randomized, double-blind, placebo-controlled studies to … [Read more...]

07.01.2016

Low-dose naltrexone: An effective treatment for ME/CFS?

The following article on low-dose naltrexone for ME/CFS was first published on Prohealth.com. It is being reprinted here with permission from the editor.  Unlike fibromyalgia, there are no FDA-approved treatments for ME/CFS, leaving few options for relieving symptoms. But in recent years, a growing number of patients have started using a little-known drug called low-dose naltrexone (LDN) as an off-label treatment, and now an Alabama-based researcher is planning the first trial to find out if LDN actually reduces the symptoms of ME/CFS. The FDA approved naltrexone to treat addiction to … [Read more...]

05.26.2016

Three new fibromyalgia drugs could be on the way

The following article on new fibromyalgia drugs was first published on NationalPainReport.com and is being reprinted here with permission from the editor. Updated 8/15/17 During the year following my fibromyalgia diagnosis, my rheumatologist prescribed five different drugs in an attempt to relieve my pain. None of them worked. The current fibromyalgia drugs on the market are notoriously ineffective. I remember my rheumatologist sharing a surprising statistic that I’ve since verified through my own research: The most effective fibromyalgia drugs only provide at least a 50 … [Read more...]

05.18.2016

IMC-1 antiviral combo may be next blockbuster fibromyalgia drug

This story on Dr. William "Skip" Pridgen's IMC-1 fibromyalgia drug combination was first published on NationalPainReport.com and is being reprinted here with permission from the editor.  Is IMC-1 the next big thing? A general surgeon with a small practice in Tuscaloosa, Alabama, Dr. William “Skip” Pridgen admits he’s an unlikely creator for the next blockbuster fibromyalgia drug. But the U.S. Food and Drug Administration (FDA) has fast tracked Pridgen’s novel pairing of famciclovir (Famvir), a common antiviral, with celecoxib (Celebrex), an anti-inflammatory arthritis drug, for a … [Read more...]

Wordpress content guard plugin by JaspreetChahal.org